Lytix Biopharma AS

Lytix Biopharma ASA, a clinical stage biotech company, develops novel cancer immunotherapies for cancer therapy in Norway. Its lead product candidate is LTX-315, an oncolytic molecule that is developed for intratumoral injections, is designed for the local treatment of solid tumors that is in Phase II clinical trials. The company's products also include LTX-401, an oncolytic molecule for targeting deep-seated lesions, such as liver cancer and is in a preclinical phase. It has a strategic partnership with Aurelius Biotherapeutics LLC to investigate and develop LTX-122 for the veterinary medicine market. The company was founded in 2003 and is based in Oslo, Norway. Show More...